Complete genomics inc (GNOM)
Income statement / Quarterly
Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Revenue

7,276

8,693

3,908

2,469

4,177

5,865

6,833

4,161

1,089

Cost of revenue

7,228

8,122

5,298

7,423

8,182

6,122

6,582

-

-

Start-up production costs

-

-

-

-

-

-

-

6,007

4,908

Research and development

8,867

8,946

8,693

8,309

9,546

8,028

6,808

4,954

4,928

Sales and marketing

3,678

4,642

5,253

4,307

3,455

3,138

2,700

1,591

1,313

General and administrative

4,675

3,581

4,136

3,981

3,810

3,468

2,780

2,330

1,763

Restructuring charges

144

1,496

-

-

-

-

-

-

-

Total cost and expenses

24,592

26,787

23,380

24,020

24,993

20,756

18,870

14,882

12,912

Loss from operations

-17,316

-18,094

-19,472

-21,551

-20,816

-14,891

-12,037

-10,721

-11,823

Interest expense

674

735

764

783

799

810

340

908

833

Interest and other income (expense), net

1

2

4

12

9

-258

-84

-8,827

25

Net loss

-17,989

-18,827

-20,232

-22,322

-21,606

-15,959

-12,461

-20,456

-12,631

Deemed dividend related to beneficial conversion feature of Series E convertible preferred stock

-

-

-

-

-

-

-

405

-

Net loss attributed to common stockholders

-

-

-

-

-

-

-

-20,861

-

Net loss per share - basic and diluted

-0.52

-0.55

-0.60

-0.71

-0.65

-0.56

-0.48

-21.87

-13.93

Weighted-average shares of common stock outstanding used in computing net loss per share - basic and diluted

34,334

34,079

-

-

33,076

28,290

-

-

-

Weighted-average shares of common stock outstanding used in computing net loss per share attributed to common stockholders-basic and diluted

-

-

33,482

-

-

-

25,959

954

907

Comprehensive loss

-17,989

-18,827

-20,232

-

-21,606

-15,959

-12,461

-

-